Mondobiotech

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.

Short Reads

Premium

Broad Institute, Expression Analysis, Helicos BioSciences, University of Texas at Austin, Applied Biosystems, University of Georgia, ABRF, Genomatix, Illumina, Mondobiotech, 23andMe, Kapa Biosystems

BioArray Briefs

Premium

Cancer Research UK, Fluidigm, Fox Chase Cancer Center, BioDiscovery, Mondobiotech, 23andMe

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.